Yoshimura K, Yoshioka T, Miyake O, Honda M, Yamaguchi S, Koide T, Okuyama A
Department of Urology, Osaka University Medical School, Japan.
Br J Urol. 1997 Jul;80(1):64-8. doi: 10.1046/j.1464-410x.1997.00189.x.
To clarify the role of glycosaminoglycans (GAGs) in crystal-surface binding substances (CSBS) on the growth of calcium oxalate crystals in urine.
Urine samples (24 h) were collected from healthy men (aged 25-42 years) and CSBS were obtained from the pooled urine samples. The CSBS were digested with heparitinase or proteinase and the inhibition of crystal growth assessed before and after enzyme digestion. Anion-exchange chromatography and high-performance liquid chromatography (HPLC) were used to determine the types of GAGs contained in the CSBS.
The inhibitory activity of CSBS on crystal growth decreased with concentration when digested with heparitinase or proteinase. HPLC showed that CSBS contained a small amount of dermatan sulphate and abundant heparan sulphate, both of which inhibited crystal growth.
Both heparan sulphate and dermatan sulphate may inhibit calcium oxalate crystallization, the former being the predominant GAG in CSBS.
阐明糖胺聚糖（GAGs）在尿液中草酸钙晶体生长的晶体表面结合物质（CSBS）中的作用。
收集健康男性（25 - 42岁）的24小时尿液样本，从合并的尿液样本中获取CSBS。用肝素酶或蛋白酶消化CSBS，并在酶消化前后评估晶体生长的抑制情况。采用阴离子交换色谱和高效液相色谱（HPLC）来确定CSBS中所含GAGs的类型。
用肝素酶或蛋白酶消化后，CSBS对晶体生长的抑制活性随浓度降低。HPLC显示CSBS含有少量硫酸皮肤素和大量硫酸乙酰肝素，两者均抑制晶体生长。
硫酸乙酰肝素和硫酸皮肤素均可抑制草酸钙结晶，前者是CSBS中的主要GAG。
